Stryker Corporation $SYK Stock Holdings Trimmed by JLB & Associates Inc.

JLB & Associates Inc. lessened its position in shares of Stryker Corporation (NYSE:SYK) by 18.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,723 shares of the medical technology company’s stock after selling 4,979 shares during the period. JLB & Associates Inc.’s holdings in Stryker were worth $6,839,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Citizens Financial Group Inc. RI lifted its stake in Stryker by 3.8% during the second quarter. Citizens Financial Group Inc. RI now owns 67,075 shares of the medical technology company’s stock worth $21,118,000 after purchasing an additional 2,464 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc increased its stake in Stryker by 6.2% during the second quarter. Texas Capital Bank Wealth Management Services Inc now owns 2,291 shares of the medical technology company’s stock valued at $721,000 after purchasing an additional 134 shares during the last quarter. Grandfield & Dodd LLC increased its stake in Stryker by 0.4% during the second quarter. Grandfield & Dodd LLC now owns 97,311 shares of the medical technology company’s stock valued at $30,637,000 after purchasing an additional 369 shares during the last quarter. Dunhill Financial LLC raised its holdings in shares of Stryker by 609.7% during the second quarter. Dunhill Financial LLC now owns 220 shares of the medical technology company’s stock worth $69,000 after purchasing an additional 189 shares during the period. Finally, Pallas Capital Advisors LLC lifted its position in shares of Stryker by 1.6% in the 2nd quarter. Pallas Capital Advisors LLC now owns 18,852 shares of the medical technology company’s stock worth $5,936,000 after buying an additional 293 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on SYK shares. Canaccord Genuity Group decreased their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Wells Fargo & Company cut their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Citizens Jmp cut their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a report on Monday, August 3rd. Needham & Company LLC decreased their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, BTIG Research lowered their target price on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Stock Performance

Shares of SYK opened at $331.96 on Wednesday. The firm has a fifty day moving average of $325.56 and a 200-day moving average of $333.05. The company has a market cap of $127.33 billion, a price-to-earnings ratio of 34.40, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 315,370 shares of company stock worth $98,463,501. 4.60% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.